Contact Information: Contacts: Kevin Krenitsky Chief Executive Officer BioServe 610-304-8784 Email Contact Constantine Theodoropulos Boston Communications 617-619-9801 Email Contact
BioServe Names Kevin Krenitsky as Chief Executive Officer
| Source: BioServe
BELTSVILLE, MD -- (MARKET WIRE) -- May 7, 2007 -- BioServe today strengthened its senior
management team with the appointment of Kevin Krenitsky, M.D. as Chief
Executive Officer. Krenitsky is a highly respected 15-year veteran of the
life sciences industry, bringing a wealth of experience in building and
managing global biotechnology operations.
"Kevin's impressive range of experience in diagnostics, pre-clinical and
clinical pharma, along with his in depth knowledge of our recently acquired
Genomics Collaborative bio-banking business makes him the perfect fit to
lead BioServe into the future," said Rama Modali, Founder and President,
BioServe. "Kevin's operational experience along with his successful
experience in launching new products and service offerings will be
instrumental in growing BioServe's global business. We are pleased that
Kevin has joined BioServe and look forward to his contributions to the
team."
Prior to joining BioServe, Dr. Krenitsky was the Chief Executive Officer of
Parkway Clinical Laboratories, a clinical diagnostic lab providing
comprehensive routine and esoteric testing. Prior to that he served as
Senior Vice President and Division Head at SeraCare Life Sciences' Genomics
Collaborative Division (GCI) where he managed all worldwide pharmaceutical
R&D collaborations. Before GCI was acquired by Seracare Life Sciences, Dr.
Krenitsky acted as the company's Medical Director responsible for
spearheading the development of GCI's global network of five hundred-plus
clinical sites on four continents. During his tenure at GCI, Dr. Krenitsky
was instrumental in developing several hundred agreements with dozens of
major pharmaceutical, biotechnology, and diagnostic companies worldwide.
Dr. Krenitsky received his M.D. from Jefferson Medical College.
Dr. Krenitsky commented, "I am extremely excited to join BioServe, a
company that has forged a stellar reputation for genomic analysis among
many of the world's leading researchers. With the addition of the Genomics
Collaborative bio-bank to the company's comprehensive services, BioServe is
on track to become the leader in helping researchers discover and validate
a new generation of superior diagnostic and therapeutic targets."
About BioServe
BioServe provides a comprehensive 'biomaterial to validated data' genomics
services platform, helping researchers gain the pre-clinical data for
breakthroughs in drug discovery, molecular diagnostics and
pharmacogenomics. Utilizing BioServe's genomics services platform,
researchers can identify genetic markers, validate drug targets that cause
disease and correlate clinical data with molecular data to accelerate the
development of new and safer drugs. BioServe's services extend from nucleic
acids processing, DNA synthesis, high throughput sequencing and genotyping,
genome wide-scans and gene expression analyses to ready-made large
epidemiologically sound case-control studies of inflammatory disorders,
endocrine disorders, cardiovascular disease, diabetes, hypertension,
obesity and many cancers. BioServe's Global Repository® provides
researchers with a library of 600,000 human DNA, tissue and serum samples
linked to detailed clinical and demographic data from 140,000 consented and
anonymized patients from four continents. BioServe's customers include
leading pharmaceutical and biotechnology companies, and government and
academic research institutions. BioServe has headquarters in Beltsville, MD
and Hyderabad, India. For more information please visit www.bioserve.com or
call 301-470-3362.